


# FIGURE 1

Western Blot of Flk-1/SEAPS Immunoprecipitation with MAb  
DC101

Flk-1  
AP




# FIGURE 2A



**Probe: Anti-Ptyr**

## FIGURE 2B

MAb ( $\mu\text{g/ml}$ )	-	-	.5	1	2.5	5
VEGF (40 ng/ml)	-	+	+	+	+	+



Probe: Anti-Ptyr

## FIGURE 3A


MAb (5 $\mu$ g/ml)  
VEGF (ng/ml)

+	+	+	+	-	-	-	-	+
80	40	20	10	80	40	20	10	-



Anti-Ptyr

FIGURE 3B



## FIGURE 4

Inhibition of VEGF-Flk-1/fms activation by pre-bound MAb DC101

Assay conditions:

					<b>P</b>	<b>C</b>
<b>MAb (5μg/ml):</b>	-	+	-	-	$\sqrt{+}$	$\sqrt{+}$
<b>VEGF (ng/ml):</b>	-	-	20	40	40	40




**Probe: Anti-Ptyr**

Assay conditions: P: MAb pre-bound 15'; VEGF 15'  
 C: Competitive assay; MAb  
 + VEGF 15'

200280 TT-000001




## FIGURE 5



202280.11400001



**FIGURE 6** FACS ANALYSIS OF Anti-flk-1 MAB BINDING TO flk-1/fms TRANSFECTED 3T3 CELLS (C441)






20020811 11:22:00



**FIGURE 7** SATURATION BINDING OF MAb DC101 TO THE  
flk-1/ $\text{trms}$  RECEPTOR ON THE TRANSFECTED 3T3 CELL LINE C441



## FIGURE 8

Immunoprecipitation of phosphorylated Flk-1/fms from  
VEGF stimulated Flk-1/fms transfected 3T3 cells

**Antibody: 1 2 3 4**

  - 200

**Anti-pTyr**


- Antibodies:
- 1) Rat anti-flk-2 IgG<sub>2a</sub> 2A13
  - 2) Rat anti-flk-1 IgG<sub>1</sub> DC101
  - 3) Rat anti-flk-2 IgG<sub>1</sub> 23H7
  - 4) Rabbit anti-fms polyclonal IM 133



## FIGURE 10

Effect of MAb DC101 on CSF-1 induced phosphorylation of the *fms* receptor


<b>MAb (5μg/ml)</b>	-	+	-	-	+	+
<b>CSF-1 (ng/ml)</b>	-	-	20	40	20	40



Probe: Anti-Ptyr

# FIGURE 11

Specificity of MAb DC101 neutralization of the activated Flk-1/fms receptor



Rat MAbs: 1) Anti-flk-1 IgG<sub>1</sub> DC101  
 2) Anti-flk-2 IgG<sub>1</sub> 23H7  
 3) Anti-flk-2 IgG<sub>2a</sub> 2A13



# FIGURE 13

Immunoprecipitation of phosphorylated receptor bands from  
VEGF stimulated HUVEC cells





FIGURE 14





# Effect of MAb DC101 on VEGF Receptor Forms in the Tumor Cell Lines A431 and 8161





Figure 15

FIGURE 16A

TREATMENT OF GLIOBLASTOMA  
 XENOGRAFTS WITH RAT anti-flk-1 MAb



STATISTICAL ANALYSIS


flk-1 SLOPE = 16.09

p VALUE FOR flk-1 VERSUS flk-2 TUMOR SIZE = 0.0001



FIGURE 16B

TREATMENT OF GLIOBLASTOMA  
XENOGRAFTS WITH RAT anti-flk-2 Mab



STATISTICAL ANALYSIS

flk-2 SLOPE = 37.39

p VALUE FOR flk-1 VERSUS flk-2 TUMOR SIZE = 0.0001

20020811100001

FIGURE 17

